Apixaban Use in Chronic Kidney Disease

Introduction to Apixaban in CKD

• The American College of Cardiology recommends non-vitamin K antagonist oral anticoagulants (NOACs) like apixaban over vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in CKD G1-G4 patients with chronic kidney disease, with appropriate dose adjustments based on renal function 1, 2

Dosing Recommendations Based on Kidney Function

• For patients with CKD stages G1-G3 (CrCl >30 mL/min), standard apixaban dosing can be used 1, 2
• For patients with CKD stage G4 (CrCl 15-29 mL/min), apixaban should be prescribed at a reduced dose of 2.5 mg twice daily 3

Evidence Supporting Use in Advanced CKD

• Apixaban has the lowest renal clearance (27%) among NOACs, making it potentially more suitable for patients with impaired renal function 3

Monitoring Recommendations

• Regular monitoring of renal function is essential in CKD patients on apixaban, with more frequent evaluation recommended for those with CrCl <60 mL/min 3

Special Considerations for Dialysis Patients

• The American College of Cardiology recommends apixaban 5 mg twice daily for ESRD patients on stable hemodialysis, with dose reduction to 2.5 mg twice daily if the patient is ≥80 years or weighs ≤60 kg 4

Safety Considerations

• When considering apixaban in CKD patients, assess both stroke risk (using CHA₂DS₂-VASc) and bleeding risk (using HAS-BLED) 3, 5

Clinical Pitfalls and Caveats

• When discontinuing apixaban before procedures, the timing depends on renal function and bleeding risk of the procedure - for CrCl 30-50 mL/min, discontinue ≥48 hours before high-risk procedures 2, 5